Product Description
A recombinant agent chemically identical to or similar to the endogenous cytokine interleukin-4 (IL-4). Produced primarily by activated T cells, IL-4 binds to and activates its cell-surface receptor, stimulating the proliferation and differentiation of activated B cells and enhancing their ability to present antigens to T cells. As a potential immunotherapeutic agent, binetrakin also augments the effects of other cytokines on dendritic cells (DC), cytotoxic T lymphocytes (CTL), and tumor-infiltrating lymphocytes (TIL). (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/binetrakin?redirect=true)
Mechanisms of Action: IL4 Analogue
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|